Translational Relevance: Etirinotecan pegol is a unique, long acting topoisomerase I inhibitor that provides prolonged systemic exposure to . In this study, 76 patients with refractory tumors were treated on various dose levels and schedules. Dose limiting toxicities included late, non-cholinergic diarrhea and neutropenia, both manageable with dose modifications. In this phase I trial, 25 (32.9%) patients demonstrated some type of antitumor effect; eight (11%) had a confirmed partial response to treatment including one patient with colon cancer who had experienced disease progression on a prior irinotecan based regimen. Two (2.6%) additional patients had an unconfirmed partial response. The benefit of the prolonged SN-38 t 1/2 of 50 days following etirinotecan pegol administration appears to be translational to the clinic. The agent is being actively studied in ongoing phase II and III trials. Research.
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Introduction
Etirinotecan pegol is a unique, long acting topoisomerase I inhibitor that provides prolonged systemic exposure to SN-38 the active metabolite of irinotecan, which is primarily responsible for its efficacy (1) , at the site of the tumor. Irinotecan, an antineoplastic agent of the topoisomerase I inhibitor class, is widely used to treat patients with colorectal cancer and other solid tumors (1-10). SN-38 binds to and stabilizes the topoisomerase I-DNA complex, leading to single-and double-stranded DNA breaks and inhibiting DNA repair. Irinotecan and SN-38 have terminal elimination half-lives (t 1/2 ) of 9 to 12 hours and 12 to 47 hours, respectively (1, 11) . Irinotecan treatment can be associated with severe diarrhea and severe neutropenia, limiting the frequency with which it can be administered to patients. Therefore, irinotecan is typically administered every 14 to 21 days, which results in a better safety profile than the weekly administration of irinotecan.
Etirinotecan pegol is designed to reduce maximal SN-38 systemic concentrations while providing continuous exposure to tumors, even when administered in 14-or 21-day cycles. The pharmacokinetic (PK) profile of etirinotecan pegol leads to both improved efficacy and safety compared with irinotecan in preclinical models of cancer.
In mouse models of human tumors, etirinotecan pegol resulted in marked dose-related and sustained tumor growth inhibition in colorectal, lung, breast, and ovarian cancers (2, 6 and correspondingly greater systemic exposure to SN-38, following etirinotecan pegol dosing, compared with irinotecan. These animal studies suggest that etirinotecan pegol may be more efficacious than irinotecan because of greater topoisomerase I inhibition resulting from prolonged tumor cell exposure to SN-38 (12) .
The primary objectives of this first-in-human phase 1 clinical trial were to characterize the safety profile and establish a maximum tolerated dose (MTD) of etirinotecan pegol following three separate dosing regimens in patients with refractory solid tumors.
Secondary objectives included the determination of the plasma PKs and metabolites, as well as an evaluation of clinical antitumor activity of etirinotecan pegol.
Materials and Methods

Patient Selection
Eligible patients had histologically confirmed, evaluable, or measurable malignant solid tumors, metastatic or unresectable, for which standard curative or palliative treatments do not exist. All were required to be ≥18 years of age, have an Eastern Cooperative Oncology Group performance status of 0 or 1, with an estimated life expectancy of ≥12 weeks. Other eligibility criteria included adequate organ/bone marrow function, absolute neutrophil count ≥1,500/mm 3 without colony-stimulating support for 3 weeks, white blood cell count ≥3,000/mm 3 Patients were excluded from the trial if they had received chemotherapy, including any investigational agents or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the commencement of dosing. In addition they must have recovered to at least a grade 1 toxicity, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0, (CTCv3.0); alopecia of any grade was allowed. Additional exclusion criteria included major surgery within 4 weeks; pregnant or nursing; unstable symptoms from brain metastases; serologically positive for hepatitis B or C, or history of human immunodeficiency virus; cerebrovascular accident or transient ischemia; and history of hypersensitivity to irinotecan, other camptothecin derivatives, or pegylated drugs. The presence of the UGT1A1*28 allele was assessed for heterozygosity or homozygosity, but it was not exclusionary. The study received approval by the Western Institutional Review Board and each institutional ethics board. The study was conducted in accordance with the provisions of the Declaration of Helsinki (13) .
Study Drug
Etirinotecan pegol was manufactured by Nektar Therapeutics, San Francisco, CA, and supplied in amber glass vials containing lyophilized etirinotecan pegol powder equivalent to 100 mg irinotecan. Each patient's dose was reconstituted with 5% Dextrose Injection, USP (D5W), total volume 500 mL, to final concentrations of 0.12 to 2.8 mg irinotecan equivalents/mL, and administered via intravenous infusion over 90 minutes. The reconstituted drug required protection from direct ambient lighting at room temperature (15 to 30°C) for up to 2 hours prior to start of infusion and drug could also The protocol recommended that patients receive premedication with antiemetic agents including dexamethasone given in conjunction with a 5-HT3 at least 30 minutes before administration of etirinotecan pegol, and written instructions for aggressive anti-diarrheal treatment.
Study Design
This was a multicenter, first-in-human, open-label, phase 1, dose-escalation study of etirinotecan pegol in patients with advanced refractory tumors. All patients received the study drug by intravenous (IV) infusion over 90 minutes. Three etirinotecan pegol treatment schedules were evaluated: (1) antiemetic or antidiarrheal regimen; any other grade 3 or higher nonhematologic toxicity that occurred during the study, unless it was clearly unrelated to etirinotecan pegol (e.g., because of disease progression); or a toxicity within the first 21 days of cycle 1 in the treatment group 1 (w×3q4w) and treatment group 2 (q21d) dosing schedules or within the first 14 days of cycle 1 in the treatment group 3 (q14d) dosing schedule that made the administration of the study drug impossible. The highest dose of etirinotecan pegol in which <33% of patients experienced a DLT was considered the MTD (14) . Once the MTD was determined, additional patients were accrued at that dose to further characterize its safety and tolerability in the dosing schedule.
The initial wx3q4w schedule was chosen based on prior clinical experience with irinotecan. Subsequent expansions of the schedule to q14d and q21d were driven by clinical observations at each dose/schedule combination, and by initial PK data suggesting that disposition and elimination in humans were notably slower than observed in animals. To allow comparisons between etirinotecan pegol and irinotecan, plasma irinotecan and SN-38 concentration-time profiles after irinotecan administration were simulated using a population PK model for irinotecan (16) .
Statistical Methods
The safety population included all enrolled patients who received at least one dose (or partial dose) of etirinotecan pegol. Safety, PK, and tumor evaluation data were summarized using descriptive statistics.
Results
Patients
The demographics of patients in this study were similar across the three treatment schedules (Table 1) . A total of 76 patients with a wide variety of solid tumors were enrolled in this trial. The most commonly represented anatomical locations for the primary tumor were lung (n=18), colorectal (n=17), pancreas (n=5), ovary (n=5), cervix (n=5), esophagus (n=5), and breast (n=4). Aside from the time since prior systemic chemotherapy, other trends in the patients' medical histories were similar across the three treatment arms.
Dose Escalation
In treatment group 1 (w×3q4w), dose escalation continued until the maximum and the observation that 4 of 12 patients experienced grade 3 diarrhea after the protocol defined DLT window limited to the first cycle, the investigators and sponsor agreed to reduce the MTD to the next lower dose level of 145 mg/m2 in both the 14-and 21-day schedules. Additional patients were not added as 0 of the 3 treated at the 145 mg/m2 dose level in treatment groups 2 and 3 experienced a DLT.
Safety
All patients experienced one or more treatment-emergent adverse events during the study. The most clinically significant AEs related to study drug across all cycles of treatment were gastrointestinal disorders, including diarrhea, nausea, and vomiting (Table 2 ). In treatment group 1, at doses ≤115 mg/m 2 , 7 of 9 (78%) patients' reported diarrhea (1 with grade 3) and nausea with only 3 of 9 (33%) reporting vomiting.
However, as the dose escalated to ≥145 mg/m 2 , all patients treated reported diarrhea from grade 1 to 3 along with a higher incidence of nausea and vomiting. In treatment group 2, 7 patients (78%) experienced diarrhea and 6 patients (67%) experienced nausea at doses of ≤170 mg/m 2 , with 2 patients (22%) having grade 3 diarrhea. In treatment group 3, 6 patients (67%) experienced fatigue, diarrhea, and nausea at doses of ≤170 mg/m 2 , with 1 patient (11%) having grade 3 fatigue and 4 patients (44%) having grade 3 diarrhea. Prevention and management of diarrhea included prompt initiation of loperamide 4 mg orally, at the first change in bowel habits, then 2 mg every two hours during the day and 4 mg every four hours at night until the patient was free of diarrhea for at least 12 hours (17) . Other interventions included Lomotil™, activated charcoal (18) , octreotide (19) , tincture of opium, and neomycin (20, 21) . Management of Over the course of the study, 11 deaths were reported. Two of the deaths were considered to be related to the study drug; the remaining 9 were not, with 8 attributed to disease progression, and 1 attributed to cardiopulmonary arrest (probable result of malignancy related pulmonary embolus or aspiration). The 2 deaths related to the study drug were attributed to neutropenic sepsis (n=1; 245 mg/m 2 q21d) and diarrhea (n=1; 220 mg/m 2 q14d). Nine patients experienced unexpected AEs, including involuntary muscle contractions and twitching, but all of these were painless and resolved within 24 hours. The underlying mechanism for these AEs is unclear, and these patients had no significant electrolyte abnormalities. Drug-related blurred vision, grade 1, that was transient and that resolved spontaneously occurred in 10 patients (13%).
PK Data
Research. Plasma NPC concentrations were near the limit of quantitation and patient variable, precluding meaningful PK analysis of this metabolite. Steep declines in concentrations during the initial disposition phase were observed for etirinotecan pegol and irinotecan, whereas SN-38, SN-38-G, and APC showed more shallow declines from maximal concentrations (see Fig. 1 ).
Importantly, trough concentrations of irinotecan, SN-38, SN-38-G, and APC were detectable after etirinotecan pegol dosing with all three schedules, providing evidence of sustained exposure between dosing intervals even when administered q21d. The exposure pattern for etirinotecan pegol is different from those for irinotecan and SN-38 after irinotecan administration where concentrations fall below quantitation limits before the next dose is administered.
In general, the plasma concentrations of all analytes increased in proportion to the etirinotecan pegol dose, independent of the dosing schedule, with C max after the first dose increasing linearly with the size of the first dose and cumulative AUC increasing linearly with the total dose administered for etirinotecan pegol, irinotecan, and SN-38 (Fig. 2a) . Similar plots were obtained for the remaining metabolites.
Research. (Fig. 2b) .
Mean PK parameter values are presented in Table 3 
The reported interpatient variability for SN-38 after irinotecan administration ranges between 40% and 58% (16, 23) , which is similar to the interpatient variability observed for SN-38 after administration of etirinotecan pegol.
Evidence of Response
Seventy-three of the 76 patients (96.1%) with a variety of solid tumors had measurable disease at baseline and were, therefore, assessable for response by RECIST 1.0.
Twenty-five (32.9%) patients demonstrated some type of antitumor response; eight (11%) had a partial response to treatment confirmed by RECIST 1.0, including two patients in treatment group 1 (6.5%; 2/31), one patient in treatment group 2 (4.3%; 1/23), and five patients in treatment group 3 (26.3%; 5/19). Two (2.6%) additional patients had an unconfirmed partial response. The median duration of response was 86 days (range, 60-273 days) ( Table 4 ). The longest observed confirmed partial response of 9 months was seen in a 47-year-old male with a neuroendocrine tumor of the sinus.
The anatomical locations of primary tumors for patients with confirmed partial responses were lung (n=2), colorectal (n=1), pancreas (n=1), breast (n=1), cervix (n=1), bladder (n=1), and head and neck (n=1). The assessments, which did not meet formal RECIST guidelines, revealed that in the 17 patients with signs of antitumor response, two (colorectal and ovarian tumors) had unconfirmed partial responses, three (esophagus, ovarian, and breast tumors) had declines in tumor markers suggestive of antitumor activity, and 12 had stable disease with durations ranging from 99 days to 343 days.
Excluding stable disease as a measure of antitumor activity, more antitumor activity was seen in patients treatment group 1 (15.6%; 5/32) and treatment group 3 (36.8%; 7/19) than in treatment group 2 (4.0%; 1/25). However, in general, there were too few patients in each group to perform comparative analyses.
Discussion
Etirinotecan pegol, is a unique long acting topoisomerase I inhibitor that provides prolonged systemic exposure to SN-38. This first-in-human study demonstrates that etirinotecan pegol has significant antitumor activity in patients with various solid tumors and some differences in safety profile compared with the irinotecan historical profile.
Data from this study presents the versatility of etirinotecan pegol to provide several successful therapeutic regimens.
Due to the long t 1/2 of etirinotecan pegol, defining the MTD based on the first cycle of treatment was challenging. The protocol stipulated that only adverse events in the first cycle were considered DLT's. The cycle lengths varied between schedules from 2-4 weeks. It was not until patients received additional cycles that we started seeing rather severe diarrhea. As a result, we evaluated successive downward dose reductions in additional patients. For treatment group 1 (w×3q4w), dosing went from 58→115→173→230→173→145→115mg/m2, which was the determined dose that could be tolerated for multiple cycles. Patients in treatment groups 2 (q21d) and 3 (q14d), had similar experiences with doses of 145→170→195→220→245→220→ 195→170mg/m2, and 145→170→195→220→195→170mg/m2 respectively. Overall, the MTD for treatment group 1(w×3q4w), was declared to be 115 mg/m (Fig 2b) is approximately 80% of the predicted steady-state AUC; therefore neither rapid nor extensive additional accumulation is expected when the recommended q21d schedule is used.
Once etirinotecan pegol is metabolized to irinotecan, the irinotecan metabolic profile is the same as that for irinotecan administration. However, the rates of formation for each metabolite are much slower and the proportions formed are very different than those after administration of irinotecan. These differences can be characterized as a shift away from hepatic oxidation of irinotecan to APC and NPC via CYP3A4. This may be secondary to protection of irinotecan from metabolism while bound to the polymer core, as well as a corresponding greater proportion of irinotecan metabolized to SN-38 once released from the polymer core.
Diarrhea is an ongoing concern in the development of new topoisomerase I inhibitors as SN-38 levels in the intestinal lumen play a key role in the delayed diarrhea that limits dose intensification and efficacy. Encouraging work is being done to identify potent and selective inhibitors of bacterial b-glucuronidases to eliminate the GI toxicity of irinotecan without killing the bacterial symbiotes required for intestinal health. (28) These developments, if successful, may enhance the efficacy and tolerability of this class of antineoplastic.
In conclusion, in this first-in-human study, the MTD was established for the administration of etirinotecan pegol following three different dosing schedules.
Etirinotecan pegol demonstrated anti-tumor activity in a broad spectrum of cancers. An optimal response profile was seen with sustained exposure to SN-38 throughout a 21-day dosing interval in patients with lower peak concentration. An improved safety profile regarding hematologic toxicity was noted when compared historically to Table 2 . Most common adverse events related to etirinotecan pegol across all cycles of study treatment (occurring in ≥10% of patients in each treatment schedule). Nausea  3  0  4  0  3  1  13  1  3  0  26  2  Fatigue  3  0  2  2  3  0  6  0  1  0  15  2  Vomiting  1  0  2  0  2  1  8  1  2  0  15  2  Anorexia  0  0  1  0  4  2  7 0  0  2  0  2  1  2  1  3  1  9  3  Anemia  0  0  1  0  1  1  1  0  2  1  5  2  Anemia  0  0  1  0  1  1  1  0  2  1  5  2  Anorexia  0  0  1  0  0  0  1  0  3  2  5  2  Hypomagnesemia  0  0  1  0  1  0  1  0  2  0  5  0  Abdominal Fatigue  2  0  4  1  4  0  5  2  15  3  Nausea  3  0  3  0  4  0  5  1  15  1  Diarrhea  2  2  4  2  4  1  4  3  14  8  Vomiting  3  0  2  0  2  0  3  1  10  1  Anorexia  1  0  1  0  2  0  3  0  7  0  Alopecia  1  0  2  0  1  0  2  0  6  0  Abdominal %CV, coefficient of variance; C max / dose, maximum observed plasma concentration after administration of the first dose divided by the first etirinotecan pegol dose; T max , time that C max was observed; AUC/dose, area under the concentration vs time curve from t=0 through end of dosing divided by the total etirinotecan pegol dose; CL, total plasma clearance for etirinotecan pegol; CL/F, total plasma metabolite clearance divided by the fraction of metabolite formed; V, volume of distribution for etirinotecan pegol; V/F metabolite volume of distribution divided by the fraction of metabolite formed; t distribution for etirinotecan pegol; V/F, metabolite volume of distribution divided by the fraction of metabolite formed; t 1/2 , terminal elimination half-life. 
